AI analysis of PET scans for T-NK cell lymphoma
Part of Cancer clinical trials.
This study uses artificial intelligence to analyze PET/CT scans of people with T-NK cell lymphoma. The goal is to see if the AI can help doctors better diagnose this rare cancer, predict how well treatment will work, and forecast long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of T-NK cell lymphoma (a type of blood cancer that affects certain immune cells).
- You must have had an FDG-PET/CT scan before starting any treatment for this lymphoma.
- You will be treated with the best current standard therapy for your condition.
- Your medical records and follow-up information must be complete and available for the study.
- You cannot have received any prior treatment for this lymphoma (like chemotherapy or radiation).
- You cannot have a history of other cancers (except this lymphoma).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special PET scan to see how well treatment works for T-NK cell lymphoma. The scan looks for a protein called granzyme B, which may help predict how the disease will respond and what the outlook might be.
This trial studies whether special imaging with PET/MR can help stage (find the extent of) and evaluate treatment effectiveness in people newly diagnosed with NK/T-cell lymphoma. It may help doctors choose the right treatment plan and track how well therapy is working.
This trial uses artificial intelligence to predict if early-stage lung cancer has spread to nearby lymph nodes. It aims to help doctors make better treatment decisions for patients with stage 1 lung cancer.
This trial uses artificial intelligence (AI) to analyze standard, non-contrast CT scans to identify and understand kidney tumors. It aims to help doctors make better decisions without needing special dye injections.
This trial tests whether using artificial intelligence to guide treatment after one round of chemotherapy works better than standard treatment for a type of blood cancer called LBCL. You'll receive initial chemotherapy, then be assigned to either an AI-guided treatment plan or standard chemotherapy based on how well you respond.
This study uses artificial intelligence to analyze your preoperative MRI and pathology results to better predict if cervical cancer has spread to pelvic lymph nodes. The goal is to improve future treatment decisions for patients with cervical cancer.
Hear when a new T-NK Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.